Search Results

Dr. Larry Gold, the founder of SomaLogic, Inc. and Dr. Jason Cleveland, SomaLogic’s current Chief Technology Officer, are issuing the below letter to SomaLogic’s stockholders regarding their opposition to the Company’s proposed merger with Standard BioTools, Inc. .

SomaLogic, Inc., a leader in proteomics technology, announced that, based on the preliminary vote count provided by its proxy solicitors following the Company’s Special Meeting of Stockholders held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. .

SomaLogic, Inc., a leader in proteomics technology, sent the following open letter to stockholders reiterating the Board’s belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic at its Special Meeting of Stockholders.

SomaLogic, Inc. issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools on October 4, 2023.

SomaLogic, Inc., a leader in proteomics technology, issued the following statement in response to a press release issued by Madryn Asset Management, LP on December 26, 2023, regarding the pending merger with Standard BioTools.

SomaLogic, Inc., a leader in proteomics technology, sent the following open letter to stockholders urging them to vote “FOR” the value maximizing transaction with Standard BioTools.

SomaLogic, Inc., a leader in proteomics technology, announced that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk.

Madryn Asset Management, LP, a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc., disclosed that the Transaction Committee of the Company’s Board of Directors did not pursue a substantive dialogue with Laboratory Corporation of America Holdings – one of the industry’s most logical strategics, with a $19 billion market capitalization – before recommending shareholders vote for the proposed merger with Standard BioTools Inc.